Overview

Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Status:
RECRUITING
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer
Phase:
PHASE4
Details
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Collaborator:
Ipsen
Treatments:
cabozantinib
Nivolumab